Sanofi gains EMA Orphan Drug status for efdoralprin alfa, a phase II biologic for AATD-related emphysema with promising dosing data.

EMA grants orphan designation to Sanofi’s efdoralprin alfa for alpha-1 antitrypsin deficiency related emphysema: Paris Thursday, December 18, 2025, 13:00 Hrs [IST] Sanofi, an R& ...

Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema ...

Objective: To describe a murine model of emphysema induced by a combination of exposure to cigarette smoke (CS) and instillation of porcine pancreatic elastase (PPE). Methods: A total of 38 C57BL/6 ...

What Are Emphysema and Chronic Bronchitis? Emphysema and chronic bronchitis are both chronic obstructive pulmonary diseases (COPD) -- long-term conditions that get in the way of airflow and make it ...

Emphysema detected on baseline low-dose chest CT (LDCT) in the lung cancer screening cohort of more than 9,000 asymptomatic adults was associated with death from all causes, chronic obstructive ...

Visually assessed pulmonary emphysema independently predicted modestly elevated all-cause mortality risk over 25 years of follow-up in patients with a history of smoking. After controlling for other ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Apreo Health, a clinical-stage medical device company developing a novel, tissue-sparing treatment for severe emphysema, today announced the presentation of ...

This study is led by Dr. Lianyong Han and Dr. Tobias Stoeger in Germany (Institute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC), Helmholtz Zentrum München, German Research ...

VIENNA — Bronchoscopic lung volume reduction (BLVR) was associated with sustained improvements in adults with severe emphysema over a 5-year period, based on data from 190 individuals. The LIBERATE ...